Related Experiment Video
Updated: Apr 22, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Access to innovation in oncology from patients' perspectives: a qualitative systematic review
Allan Julliot-Delval1,2, Maria Teixeira1,2, Emmanuelle Cartron1,2,3
1Siric InsiTu, INSERM, France.
Background:
Access to innovation in oncology is commonly examined from technical, organisational, or economic perspectives, yet less is known about how patients experience access along cancer care pathways. This study synthesised qualitative evidence on adult patients' experiences of accessing innovation.
Methods:
We conducted a qualitative systematic review between Sept 1 and Oct 24, 2025, using the Joanna Briggs Institute meta-aggregation approach. MEDLINE, PsycINFO, Cairn.info, and OpenEdition were searched. Eligible studies reported adult patients' experiences of access to innovation in oncology. Findings were appraised, grouped by similarity in meaning, and aggregated into synthesised findings. Confidence was assessed using the ConQual approach. This review is registered with PROSPERO, CRD420251046315.
Findings:
20 studies involving 306 patients were included. We identified 209 findings, grouped into 13 categories and four synthesised findings. Access to innovation was described as depending on accessible information, continuity of care, conditions supporting self-management, and the availability of spaces not centred on disease.
Interpretation:
Access to innovation extends beyond availability or eligibility. It emerges as a dynamic process shaped by time, care relationships, personal resources, and organisational context. Aligning innovation with patients' lived experiences may support more equitable access.
Funding:
The Integrated Cancer Research Centre (SIRIC) InsiTu: Insights into Cancer: From Inflammation to Tumour.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:21Cancer Survival Analysis
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...